Al-Shawwa Baha A, Badi Arunkumar N, Goldberg Andrew N, Woodson B Tucker
Department of Otolaryngology and Communication Sciences, Division of Sleep Medicine, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA.
Sleep Med Rev. 2008 Dec;12(6):449-61. doi: 10.1016/j.smrv.2008.07.008.
Sleep-disordered breathing a spectrum that ranges from snoring through disorder of increased airway resistance, to overt sleep apnea affects many clinical disease outcomes. Traditionally, disease outcomes have been measured by polysomnography, with the most common metric being the apnea hypopnea index (AHI). Multiple other clinical metrics are commonly used to assess the severity and impact of disease on important outcomes of obstructive sleep apnea (OSA). These allow assessment of sleepiness, quality of life, performance, and medical, especially cardiovascular outcomes. Currently the available metrics only partially explain the associated disease outcomes in different patients. This review highlights the available clinical, physiological and biomarker metrics in measuring OSA and associated co-morbidities and defines treatment goals.
睡眠呼吸障碍是一个范围,从打鼾到气道阻力增加的紊乱,再到明显的睡眠呼吸暂停,会影响许多临床疾病的结果。传统上,疾病结果是通过多导睡眠图来测量的,最常用的指标是呼吸暂停低通气指数(AHI)。其他多个临床指标通常用于评估疾病对阻塞性睡眠呼吸暂停(OSA)重要结果的严重程度和影响。这些指标可以评估嗜睡、生活质量、表现以及医学方面,尤其是心血管方面的结果。目前可用的指标仅部分解释了不同患者的相关疾病结果。本综述重点介绍了用于测量OSA及其相关合并症的可用临床、生理和生物标志物指标,并确定了治疗目标。